AllDocs -> cancers

FA L L 2 0 0 3 VO L U M E 2 N U M B E R 3 Lymphoma Today Chapters Sizzled this Summer Bexxar TM Receives FDA Approval for NHL L R F O N L I N E Register online at www. lymphoma .org to receive the email edition of Lymphoma Today and to stay informed about the latest news in lymphoma . I N T H I S I S S U E Advocacy Advocacy 101, page 10 LYMPHOMAdvocacy, page 10 Action E-list, page 10 Chapters Chapters, cover Chapters Fall Activities, page 5 President Profile, page 5 Development Walk for the Cure, page 4 Donor Drive, page 4 Discovery Gala, page 4 West Coast Golf Classic, page 4 Education Clinical Trials, page 8 Ed Forum, page 9 Innovations inLymphomaTreatments, page 9 Research New Therapies, page 3 Research Update, page 3 Transplantation, page 6 ...

1 MEET THE EXPERT ON NON-HODGKIN LYMPHOMA : N E W I N S I G H T S A N D T R E AT M E N T S LLS 04-05 Goldberg 6/10/04 DR. GOLDBERG: Patients who have a new diagnosis of lymphoma , as well as patients who have an established diagnosis, always need to know a little bit more about their disease so that they can participate in their own care. The doctor is just one part of dealing with this disease. The doctor may give you advice on how to treat and may actually initiate the therapy, but treatment doesn’t just stop when you leave the doctor’s office. It actually starts then, as you deal with family at home, as you deal with decisions about what you’re going to do for the long-term, and the more you know about your disease, the more you know about the treatment and what may come down the road. Not only could you help the doctor, ...

Lymphoma - page 1 LYMPHOMA Lectu re da te 2004 Mar 31 Course Meds 412 - Phase 2A Lecturer Dr. David Lee Notes updated 2004 Feb 28 W H A T A R E LY M P H O M A S ? Lymphoma s are B- and T-cell neoplasms that typically result in the enlargement of lymph nodes; however, the spleen, bone marrow and other tissues may also be infiltrated. L YMPH OMA VS L EU KE M IA In general, those neoplasms which predominantly affect lymph nodes or tissues are referred to as lymphomas, and those affecting the bone marr ow w ith circula ting neo plastic c ells in the b lood as leuke mias. This distinction is both fuzzy and somewhat artificial because any lymph oid n eop lasm can hav e bo th solid a nd circ ulating co mpo nents to them. C O N C E P T U A L IZ I N G L YM P H O I D N E O P L A S ...

S P R I N G 2 0 0 4 VO L U M E 3 N U M B E R 1 Lymphoma Today LRF Announces $1,065,000 in New Research Awards Passing The Torch of LRF Leadership The highest priority of the research program of the Lymphoma Research Foundation (LRF) is to support and encourage the efforts of top fellows and scientists at the nation’s lead- ing academic institutions to expand their research efforts and accelerate the process of developing successful treatments and ultimately a cure for lymphoma . John M. Pagel, MD, PhD; of the Fred Hutchinson Cancer Research Center in Seattle, WA will receive $ 225,000 in total for his project titled Pretargeted Radioimmunotherapy for CD20+ Non-Hodgkin’s Lymphoma . The overall objective of this project is to improve the efficacy and decrease the toxicity of radioimmunotherapy for patients with relapsed non- Hodgkin’s lymphomas by dramatically improving ...

Incidence and Mortality Rate Trends Lymphoma , including Hodgkin’s lymphoma and non-Hodgkin’s lymphoma (NHL), represents approximately five percent of all cancers in the United States. While Hodgkin’s lymphoma is the better-known form of lymphoma , the incidence of Hodgkin’s lymphoma is much less than that of NHL. Due to improvements in the treatment of Hodgkin’s lymphoma , the mortality rate has significantly decreased over the past 25 years. However the incidence and mortality rates for NHL have increased, with the incidence rate nearly doubling, since the early 1970s, then stabilizing in the last five years. For both forms of lymphoma , incidence and mortality rates have been higher for Whites than African Americans and other ethnic groups. It is estimated that approximately $3 billion* is spent in the United States each year on treatment for ...

CONCISE COMMUNICATION Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti- retroviral therapy Andrew E. Grulich, Yueming Li, Ann M. McDonald, Patricia K. Correll, Matthew G. Law and John M. Kaldor Objective: To describe the changing incidence of Kaposi's sarcoma (KS) and non- Hodgkin's lymphoma (NHL) in people with HIV in Australia during the time period of introduction of potent combination anti-retroviral therapy. Design: A national, population-based linkage study of cancer and HIV registration data. Methods: We calculated person-year rates of KS and NHL in people after reporting of HIV diagnosis. Trends in cancer incidence rates were examined, based on four time periods de®ned by the availability of speci®c anti-retroviral therapies. Results: Linkage identi®ed 206 cases of KS and 235 cases of NHL in 8108 people reported with HIV ...

The lymphoma market: Keeping up in a fragmented and April 2003 competitive environment Page 2 BSG Highlight Report Lymphoma © BioSeeker Group April 2003 2 Table of contents Methodology 13 Introduction.14 Figure 1 - Number of cancer drugs in clinical trials 1991-2001.14 Table 1 - Novel approaches to cancer therapy.15 Incidence and Prevalence ..15 Market Outlook16 Current Management of Lymphoma ..17 Hodgkin's Disease ..17 Radiation Therapy17 Chemotherapy 18 Transplantation .18 Cellular Classification18 Box 1 - Updated REAL/WHO Classification for B-Cell Neoplasms..19 Stage Information.19 Treatment Option Overview ..20 Box 2 – Possible Complications of Treatment 22 Non-Hodgkin's Lymphoma ..22 Radiation Therapy23 Chemotherapy ...

37 LYMPHOMA OF THE BLADDER Case Report PRIMARY LYMPHOMA OF THE BLADDER KATIA R. M. LEITE, HOMERO BRUSCHINI, LUIZ H. CAMARA-LOPES Laboratory of Surgical and Molecular Pathology, Syrian Lebanese Hospital, São Paulo, SP, Brazil ABSTRACT Primary lymphomas of bladder are rare, have a good prognosis and present good response to chemotherapy. We report a case of primary lymphoma affecting the bladder of an 89-year old female patient who, despite full response to chemotherapy, presented recurrence and death 1 year after con- cluding the treatment. The authors emphasize the differential diagnosis due to the great differences concerning prognosis and therapeutic approach. Key words : bladder; neoplasms; lymphoma ; treatment Int Braz J Urol. 2004; 30: 37-9 Figure 1 – Magnetic resonance imaging, T1-weighted sequence showing thickening of vesical wall affecting ...

EGAM 2004 EORTC LYMPHOMA GROUP PROGRAM 14.00 - 16.00 Non-Hodgkin’s Lymphomas session 14.00 : Welcome, highlights October 03-April 04 14.05 : Minutes of the General Meeting, Rotterdam, October 2003 14.10 : Report from the Data Center 14.20 : 20013, IF radiotherapy vs chlorambucil in follicular NHL 14.30 : 20971, IF radiotherapy ± low dose TBI in follicular NHL 14.40 : 20981, CHOP ± Rituximab in relapse of follicular NHL 14.50 : 20991 & 20991, aggressive NHL in the elderly 15.05 : 20021, CHOP vs Gem-CHOP in aggressive NHL 15.20 : CNS lymphoma project 15.30 : Report from pathology & biology subcommittee 15.40 : CHVmP/BV late toxicity 15.50 : Publications on non Hodgkin’s lymphomas, new proposals 16.00 - 16.30 Coffee Break 16.30 - 18.30 Hodgkin’s session 16.30 : Report on radiotherapy subcommittee 16.40 : Report on pathology subcommittee ...

Lymphoma development in Bax transgenic mice is inhibited by Bcl-2 and associated with chromosomal instability JJ Luke 1 , CI van de Wetering 1,2 and CM Knudson* ,1,2,3 1 Department of Pathology, The University of Iowa Roy J. and Lucille P. Carver College of Medicine, Iowa City, Iowa, USA 2 Molecular Biology Program, The University of Iowa Roy J. and Lucille P. Carver College of Medicine, Iowa City, Iowa, USA 3 Immunology Program, The University of Iowa Roy J. and Lucille P. Carver College of Medicine, Iowa City, Iowa, USA * Corresponding author: CM Knudson, Department of Pathology, 200 Hawkins Drive, 3160 C ML, Iowa City, IA 52242, USA. Tel: 319-335-8147; Fax: 319- 356-0331; E-mail: c-knudson@uiowa.edu Received 23.5.02; revised 19.9.02; accepted 6.12.02 Edited by D Altieri Abstract Bax is a Bcl-2 ...

1 Intestinal lymphoma Ahmet Dogan Introduction Extranodal lymphomas account for around 40 % all lymphoid neoplasms and the most common site they occur is the gastrointestinal tract. The majority arise primarily in the gut however a significant minority of gut lymphomas is a result of secondary dissemination from other nodal or extranodal sites. The lymphomas commonly seen in the intestine are listed in Table 1. In most instances the diagnosis is established by endoscopic biopsies or core biopsies and histologic interpretation is often challenging. The common diagnostic problems in diagnosis of intestinal lymphomas are listed in Table 2. The most critical step in the histological diagnosis of a lymphoid infiltrate is to have a sufficient sample. Often multiple good quality biopsies from different sites will be required to reach a definitive diagnosis. One should resist clinical pressures ...

The anaplastic lymphomas kinase (ALK) gene is located on chromosome 2p23, and codes for a protein that is expressed in some cells of the central nervous system, but in virtually no other normal human cells. Interest in this protein among diagnostic pathologists has been related to its utility in recognizing a subset of CD30+ anaplastic large cell lymphomas (ALCL's), that show a characteristic t(2;5)(p23;q35) translocation. This translocation results in an abnormal fusion gene involv- ing the ALK gene and the nucleophosmin (NPM) gene (located on chromosome 5q35), which codes for a ubiquitously expressed nucleolar phosphoprotein that functions in transporting components of ribosomes between the cytoplasm and nucleolus during the final stages of ribosome assembly. Transcription of this abnormal NPM-ALK fusion gene results in the produc- tion of an abnormal protein (called p80) that functions ...

GUIDELINES FOR THE MANAGEMENT OF MALIGNANT LYMPHOMA PUBLIC MEETING Date: MONDAY 15 MARCH 2004 VENUE: STAMFORD AIRPORT HOTEL, SYDNEY AIRPORT TIME: 1000 TO 1600 Kindly supported by INTERNATIONAL GUEST SPEAKERS Dr Michael Pfreundschuh is Professor and Director of the Department of Internal Medicine at the University of Saarland, Homburg, Germany. He is also the lead investigator of the German High Grade non-Hodgkin’s lymphoma study group. Dr Andrew Lister is Professor and Director of the Department of Medical Oncology, St. Bartholomew’s Hospital, London. U.K. His is a major contributor to U.K. Lymphoma and Leukaemia Studies. TOPICS FOR THE DAY WILL INCLUDE Diagnostic Pathology, Hodgkin Lymphoma , Indolent and Aggressive Lymphomas, Extranodal Disease, Complication of Treatment, Consumer Issues REGISTRATION FORM – All attendees must complete ...

Center for Environmental Health Studies (617) 482-9485 44 Farnsworth Street, Boston, MA 02210 http://www.jsi.com Non-Hodgkin’s Lymphoma (NHL) and Exposure to Ionizing Radiation 1 Non-Hodgkin’s Lymphoma (NHL) and (Lymphosarcoma and reticulum cell sarcoma) Exposure to Ionizing Radiation Summary : Some evidence has been recorded of a possible connection between non-Hodgkin's lymphoma and exposure to ionizing radiation. There is possible evidence from studies conducted at Los Alamos National Laboratory. Studies of nuclear workers at other sites who have been exposed to ionizing radiation and persons exposed to the atomic bomb show an increase risk of developing non-Hodgkin's lymphoma . The National Research Council’s BEIR V committee did not address the issue of radiation- induced non-Hodgkin’s lymphoma . Non-Hodgkin's lymphoma is designated as a “specified” ...

Last revised: 11/07/03 UM Cancer Center Patient Education Document #0038 Nov 03 Ed. Online version: http://www.cancer.med.umich.edu/learn/percpathways.htm 1 University of Michigan Comprehensive Cancer Center Patient Education Resource Center (PERC) INFORMATION GUIDE Non-Hodgkin's Lymphoma The purpose of this information guide is to help patients newly diagnosed with Non-Hodgkin's Lymphoma and their families find sources of information and support. This list is not meant to be comprehensive, but rather to provide starting points for information seeking. The materials can be found at the Patient Education Resource Center of the University of Michigan Comprehensive Cancer Center in room B1-361. Reference Available in the Patient Education Resource Center on level B-1 Lymphoma Research Foundation. Lymphoma Resource ...

IMMUNOBIOLOGY The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells Carole L. Berger, Douglas Hanlon, Daniel Kanada, Madhav Dhodapkar, Vivian Lombillo, Nianci Wang, Inger Christensen, Gregory Howe, Jill Crouch, Paul El-Fishawy, and Richard Edelson In the initial stage of cutaneous T-cell lymphoma (CTCL), proliferating CTCL cells are concentrated in the epidermis in close association with an immature den- dritic cell (DC), the Langerhans cell. Be- cause long-term in vitro culture of CTCL cells has proven difficult, the in vivo association with the major antigen-pre- senting cell (APC) of the epidermis has been postulated to play a role in directly stimulating the clonal T-cell proliferation. We report that CTCL cells can be repro- ducibly grown in culture for 3 months when cocultured with immature DCs. CTCL cells ...

Spontaneous T-Cell L ymphomas in Inbred Sprague-Da wle y Rats Vol. 48 219 Lymphoma line Autopsy at Tissue Immunophenotype Karyotype Control cells Submandibular LN * CD4 + CD8 - (53%), CD4 - CD8 + (26%) n = 42; diploidy SD1/90 *** 15 th passage lymphoma CD4 - CD8 - 42,X0; -3, +2 microsomes; pseudodiploidy SD4/91 *** 15 th passage lymphoma CD4 + CD8 - 42,XX,11q+; pseudodiploidy SD5/92 *** 15 th passage lymphoma CD4 + CD8 - 42,XX,der(11,13); pseudodiploidy Primary disease Submandibular LN * CD4 + CD8 ...

Abstract. More than a decade of experimental work in an inbred subline of Sprague-Dawley rats having high incidence of spontaneous T-cell lymphoma /leukaemia is reviewed. Longitudinal follow-up of biological charac- teristics (growth, survival, haematology) of both multi- ple cases of primary disease and s.c. passaged lym- phomas as well as comparative immunophenotypic and karyotypic studies are concluded. In these T-cell lym- phomas (mostly CD4 positive), arising on the same genetic background of the inbred SD strain, the aberra- tions involving chromosome 11 have been recognized as a typical non-random cytogenetic marker. This unique rat model of lymphoblastic lymphomas/leukaemias, rel- evant to human pathology, seems to be very suitable for testing different anticancer therapeutic strategies, as it is documented by results of a number of various protocols conducted ...

Patients Against Lymphoma Patients helping Patients 1305 Mason Avenue Staten Island, NY 10306 Phone: 718-980-0635 | Fax: 801-409-5736 KarlS@Lymphomation.org www.Lymphomation.org W e are guided by our scientific advisors, the peer-reviewed literature, medical professionals fighting lymphoma , and patient questions . We continuously improve our website in response to visitor questions and patient needs . by linking you directly to reputable sources of information, such as ClinicalTrials.gov. Visit us at www.Lymphomation.org What’s Lymphoma ? L ymphoma is a cancer that affects blood cells called lymphocytes – immune cells that normally protect you from illness. Damage to genes in these cells can sometimes lead to abnormal cell behavior ...

610 OGHALAI et al Otolaryngology– Head and Neck Surgery April 1999 Aggressive cervical lymphoma presenting as airway obstruction JOHN S. OGHALAI, MD , CARLA GIANNONI, MD , DONALD T. DONOVAN, MD , PAUL E. JOHNSON, MD , and LINDA K. GREEN, MD , Houston, Texas N on-Hodgkin’s lymphoma (NHL) is the second most com- mon malignancy of the head and neck. 1 Patients with NHL typically have persistent, painless peripheral lymphadenopa- thy, often in the cervical region, although 12% have systemic symptoms of fever, night sweats, and weight loss. 1 More than half of head and neck lymphomas occur in Waldeyer’s ring, and a third occur in extralymphatic sites, including the sinus- es, nasal cavity, oral cavity, larynx, salivary glands, ...

Primary Gastric T-cell Lymphoma Associated with Human T-cell Leukemia Virus Type I shows Lymphoepithelial Lesions : Case report Tadashi Yoshino ,Ichiro Yamadori ,Tadateru Hasuo , Hiroaki Oue ,Tadayoshi Kunitomo ,Sumie Takase , Kazuhiko Hayashi ,Yoshito Sadahira ,and Tadaatsu Akagi We describe an unusual case of adult T-cell leukemia/ lymphoma (ATL)appearing in a 44-year-old female without leukemic change and systemic lymphadenopathy,which originated from the gastric wall and partially involved the paragastric lymph nodes. No other intraabdominal or intrathoracic organs, such as the liver,spleen,kidneys,adrenals,lungs,or bone marrow,were involved at the time of surgery. The clinical stage of this case was evaluated as IIE according to the Ann Arbor classification. Lymphoma cells were CD3+,CD4+,CD8-,and CD79a-. Southern blot analysis revealed monoclonal integration of proviral DNA from human T-cell ...

Unusual case of cutaneous T-cell lymphoma with a prominent reactive population of B lymphocytes Yoshihiro Nozawa ,Kazuhiro Tasaki ,Mikio Ohtsuka ,Keiji Iwatuki , Kunihiko Tominaga and Masafumi Abe Department of Pathology Department of Dermatology, School of Medicine, Fukushima Medical University, Fukushima, Japan. Surgical Pathology Division, Takeda General Hospital, Aizuwakamatu, Japan A 58-year-old Japanese woman presented an eruption in the region of the back and the upper extremities, a subcutaneous nodule on the right breast, and a left cervical lymphadenopathy. The excision biopsy specimens, of a subcutaneous nodule and a lymph node, showed a vaguely nodular growth pattern comprising a small CD20 IgD lymphocyte infiltrate around clusters of medium-sized or large CD3 lymphoid cells, in which histological distinction between malignant lymphoma and reactive lymphoid hyperplasia was difficult. ...

Treatment outcome of nasal NK-cell lymphoma : A report of 12 consecutively-diagnosed cases and a review of the literature Motoko Yamaguchi ,Shoko Ogawa ,Yoshihito Nomoto , Kouji Oka ,Masanori Taniguchi ,Kazunori Nakase , Tohru Kobayashi ,and Hiroshi Shiku Second Department of Internal Medicine and Department of Radiology, Mie University School of Medicine, Tsu, Japan ; Department of Internal Medicine, Suzuka Kaisei General Hospital, Suzuka, Japan We retrospectively reviewed the clinical courses of 12 consecutively-diagnosed cases of localized, nasal NK-cell lymphoma . All patients revealed a phenotype of CD2+CD3(Leu4)-cytoplasmic CD3e+ CD5-CD45+CD56+. Nine patients were stage I,and three stage II. Seven patients were initially treated with an anthracycline-containing regimen (Group 1). All but one patient failed to achieve a complete response(CR)and died of lymphoma within six months of ...

Spectrum of Malignant Lymphoma in Sarawak General Hospital Suat-Cheng Peh ,Henry R Gudum ,Yan-Chin Tai , Fei-Ling Wong and Jamil Dolkadir Departments of Pathology, University of Malaya, Kuala Lumpur University of Malaysia, Sarawak Departments of Pathology, University of Malaya, Kuala Lumpur Departments of Pathology, University of Malaya, Kuala Lumpur Sarawak General Hospital, Kuching, Malaysia Recent epidemiological studies reported changing trend of lymphoid neoplasia in the past few decades. Previous study of lymphomas from East Malaysia from 1981 to 1983 showed a pattern similar to other Asian countries, except for low incidence of peripheral T-cell lymphoma in Sarawak. Current study analyzed materials from 1996 to 1998,with the aim to elucidate possible change in disease pattern, if any,in Sarawak 15 years later. A total of 70 re-confirmed lymphoma cases were classified using WHO ...

The Pattern of Burkitt s Lymphoma in Malaysian Patients Suat-Cheng Peh ,Yan-Chin Tai ,Lian-Hua Kim , Shaminie Jairaman ,Shiaw-Sze Gan and Hai-Peng Lin Endemic and sporadic Burkitt s lymphoma differ in site and age of presentation, and Epstein-Barr virus (EBV)association. This study aimed to describe the clinical presentation,EBV association and p53 expression of Burkitt s lymphoma in 59 Malaysian patients. Expression of Bcl-2, retinoblastoma and Ki67 proteins was also investigated. EBV was detected by EBER in situ hybridization. Expression of p53, Bcl-2, pRb and Ki67 proteins was detected by immunohistochemical staining. Polymerase chain reaction was employed for EBV subtyping and detection of translocation t (14; 18). The male to female ratio was 3.9 : 1. The most common age group was children younger than 15 years (72.9%),with a mean of 15.8 y. The disease is more common in ethnic Chinese. EBV association ...

CD5-Positve Diffuse Large B-Cell Lymphoma Presenting in Bone Marrow without Lymphadenopathy Naoya Nakamura ,Tetsuo Kuze ,Yuko Hashimoto ,Yoko Hara , Kazuo Watanabe ,Takanori Kawaguchi ,Kazuei Ogawa ,Shigeyuki Asano , Toshiaki Sai ,Shin Matsuda ,Hideo Sakuma and Masafumi Abe Departments of Pathology Internal Medicine, Fukushima Medical University School of Medicine, Fukushima Iwaki Kyoritsu General Hospital, Iwaki Ohta-Nishinouchi General Hospital, Koriyama In this study,we reported five cases of CD5 diffuse large B-cell lymphoma (DLBCL)which initially presented as bone marrow involvement without lymphadenopathy. The cases involved two males and three females, with an average age of 73.8 years. The patients had fever and showed general fatigue. Three of the five cases presented hepatosplenomegaly. Laboratory examination highlighted anemia, thrombocytopenia, presence or absence of leukopenia, ...

Malignant Lymphoma and Tumor Suppressor Genes Hirokazu Nagai ,Tomohiro Kinoshita ,Atsushi Ichikawa and Takashi Murate Various types of tumor suppressor genes (TSG) have been reported to be mutated in malignant lymphoma . Point mutation and deletion are the major mechanisms that inactivate TSG. Alterations of the p53 gene have been analyzed well in lymphoid malignancies,and point mutations have been proved to have an important role in the progression or aggressiveness of B cell lymphoma . Recently, the silencing of gene expression by DNA hypermethylation was proposed as an alternative mechanism in inactivation of TSG. The p73,p15INK4B,and p16INK4A genes are targets of such epigenetic alterations. The ATM, PTEN, and SNF5/INI1 genes are also reported to be mutated in T and/or B cell malig- nancies. Recurrent chromosomal deletion may indicate the loss of candidate TSGs in the deleted interval. ...

Dokumentation und Evaluation der Weiterbildung Review Article · Übersichtsarbeit Onkologie 2003;26:366–372 DOI: 10.1159/000072098 Schlüsselwörter Kutane Lymphome · B-Zell-Lymphome, kutane · T-Zell-Lymphome, kutane · Sézary Syndrom · Mycosis fungoides Zusammenfassung Die kutanen Lymphome sind eine heterogene Gruppe von lymphozytären proliferativen Erkrankungen. Die adäquate Behandlung hängt von der genauen Diagnose ab und ist in den meisten Fällen eine relativ milde Behandlung mit dem Ziel der Tumorpalliation. In Früh- stadien sind lokale Ansätze wie die Bestrahlung mit UV- oder Röntgenstrahlen sinnvoll. In fortgeschrittenen Sta- dien werden systemische Therapien wie Interferon- a oder Bexarotene empfohlen. Daneben gibt es auch eine ganze Reihe von experimentellen Ansätzen wie Vakzi- nierungsansätze ...

Detection of canine T lymphocytes in lymphoma -affected lymph nodes N. Tozon, M. [trbenc, G. Fazarinc DETECTION OF CANINE T LYMPHOCYTES IN LYMPHOMA -AFFECTED LYMPH NODES USING ANTIBODIES DIRECTED AGAINST THE HUMAN CD3 ANTIGEN N. TOZON, M. [TRBENC, G. FAZARINC Key words: veterinary medicine; immunohistochemistry; lymphoma ; CD3 antigen; dog The applicability of some commercially available antibodies directed against the human CD3 antigen in detecting canine T lymphocytes in lymphoma -affected lymph nodes was evaluated. Rabbit anti-human CD3 Dako A/S antibodies proved successful in demonstrating canine T cells, even on tissue specimens fixed in formol and embedded in paraffin wax. The antibodies recognize the intracellular fragment of the CD3 molecule, which is relatively resistant to routine histological specimen processing. Other antibodies directed against the CD3 antigen were ...